RxDoctor Payments Data

Richard Chang, MD

Interventional Cardiology · Walnut Creek, CANPI 1275669954

Payments from drug & device makers

$237,743in general payments, 2019–2025

Across 1,461 payments — averaging $162.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$88K
  • Boehringer Ingelheim$67K
  • Lilly USA, LLC$23K
  • Amgen$21K
  • Abbott$15K
  • Abiomed$3K
  • plus $21K from 54 others
$144,950in research payments, 2019–2025

Across 1 payment — averaging $144,950 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Butterfly Network, Inc.$145K

What the payments were for

  • Consulting fees$2,0002%
  • Speaking & faculty fees$82,71963%
  • Travel & lodging$8,2396%
  • Food & beverage$38,89629%
  • Education$4940%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biotronik Inc.436$87,547
Boehringer Ingelheim115$67,073
Lilly USA, LLC20$22,945
Amgen34$20,951
Abbott137$15,167
Abiomed29$2,571
Shockwave Medical, Inc40$2,254
Edwards Lifesciences39$2,199
Impulse Dynamics (USA) Inc.24$1,526
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)43$1,401
Novo Nordisk48$1,399
Johnson & Johnson90$1,331
Boston Scientific27$839
Medtronic(2 entities)14$799
Actelion Pharmaceuticals US, Inc.27$792
AstraZeneca28$714
E.r. Squibb & Sons, L.L.C.37$682
Novartis37$678
Altathera Pharmaceuticals LLC1$600
Pfizer26$530
Terumo Medical Corporation6$517
Amarin Pharma, Inc.27$506
Siemens Medical Solutions USA, Inc.6$487
Merck20$468
Esperion Therapeutics, Inc.17$387
Philips North America LLC14$364
Sanofi-aventis U.S. LLC16$310
Atricure, Inc.15$298
Cathworks, Inc.11$220
Cvrx, Inc.3$181
Inari Medical, Inc.3$155
Kestra Medical Technology Services, Inc.6$145
Bayer6$121
Heartflow, Inc.7$117
Alnylam Pharmaceuticals Inc.5$96
Lexicon Pharmaceuticals, Inc.4$95
Elutia, Inc.3$92
Cordis US CORP.1$86
Cardiva Medical, Inc.1$77
Intuitive Surgical1$72
Irhythm Technologies, Inc.4$71
Kiniksa Pharmaceuticals, Ltd.3$71
Kiniksa Pharmaceuticals International, PLC3$68
Corindus Inc.1$65
Bardy Diagnostics, Inc.2$65
Medela LLC1$60
Teleflex LLC1$56
Lundbeck LLC3$51
Baxter Healthcare2$50
Braemar Manufacturing, LLC1$45
Preventice Services, LLC1$42
Regeneron Healthcare Solutions, Inc.2$40
Angiodynamics, Inc.1$36
Medicure Pharma Inc.1$31
Daiichi Sankyo Inc.1$24
Penumbra, Inc.1$23
Reflow Medical Inc1$21
Kowa Pharmaceuticals America, Inc.1$20
Agepha Pharma FZ LLC1$18
Scpharmaceuticals Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$237,743 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$728,799
Medicare patients
1,857
Services billed
7,883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban490$660,035
JardianceEmpagliflozin295$440,059
XareltoRivaroxaban156$209,512
OzempicSemaglutide163$204,431
OpsumitMacitentan12$147,769
EntrestoSacubitril/Valsartan91$132,612
Repatha SureclickEvolocumab111$124,206
CamzyosMavacamten12$92,395
MultaqDronedarone Hcl27$55,960
BrilintaTicagrelor34$38,258
Praluent PenAlirocumab55$35,400
MounjaroTirzepatide20$28,731
Repatha SyringeEvolocumab22$18,749
FarxigaDapagliflozin Propanediol12$14,434
NexletolBempedoic Acid18$13,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$530$660,035490 claims
Boehringer IngelheimJardiance$67,073$440,059295 claims
Johnson & JohnsonXarelto$1,331$209,512156 claims
Novo NordiskOzempic$1,399$204,431163 claims
Actelion Pharmaceuticals US, Inc.Opsumit$792$147,76912 claims
NovartisEntresto$678$132,61291 claims
E.r. Squibb & Sons, L.L.C.Camzyos$682$92,39512 claims
Sanofi-aventis U.S. LLCMultaq$310$55,96027 claims
AstraZenecaBrilinta, Farxiga$714$52,69246 claims
Lilly USA, LLCMounjaro$22,945$28,73120 claims
Esperion Therapeutics, Inc.Nexletol$387$13,83818 claims
Kowa Pharmaceuticals America, Inc.Bystolic$20$4,35611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →